Katoch K, Katoch V M, Natrajan M, Bhatia A S, Gupta U D, Sharma V D, Shivannavar C T, Patil M A, Bharadwaj V P
Central JALMA Institute for Leprosy (ICMR), Tajganj, Agra, India.
Int J Lepr Other Mycobact Dis. 1995 Jun;63(2):202-12.
Thirty-six, untreated borderline lepromatous/lepromatous (BL/LL) leprosy patients with an initial bacterial index (BI) of 4+ to 6+ were serially allocated to three treatment groups. Group I patients received a slightly modified WHO regimen (rifampin once a month, clofazimine and dapsone daily) and BCG intradermally (i.d.) (0.1 mg/per dose). Group II patients were administered the same MDT and Mycobacterium w (2 x 10(8)) killed bacilli/dose i.d., and Group III received the same MDT with 0.1 ml of distilled water i.d. Vaccination was repeated every 6 months. Biopsies were taken from the local site of vaccination and from a distant site, i.e., the back. The progress was monitored periodically by clinical, histopathological and bacterial (BI, mouse foot pad, ATP) parameters. Twenty-five patients had completed a follow up of more than 2 years. These included: 7 in Group I, 10 in Group II, and 8 in Group III. One patient of the MDT + BCG group who was progressing well dropped out after 28 months. In cases on combined chemotherapy and immunotherapy, no viable bacilli were demonstrable by mouse foot pad and ATP measurement after 6 months (at 12 months or afterward). However, in come of the control cases on MDT alone, viable bacilli could be detected even up to 18 months (by mouse foot pad) and 2 years (by ATP estimation). With 36 months of treatment, the mean BI decreased from 4.64+ to 1.66+ in the group on MDT alone (controls), 4.9+ to 0.08+ in the MDT + BCG group, and 4.75+ to 0 in the MDT+Mycobacterium w group. Compared with the MDT and MDT + BCG groups, the fall in the BI was significantly more in the MDT + Mycobacterium w group at 12, 18, and 24 months. While all of the cases in the Mycobacterium w groups became smear negative by 36 months, it took 42 months for all of the BCG group to achieve negativity. Immunotherapy appears to have a significant effect on the killing and clearance of bacilli and should be considered as an adjunct to chemotherapy, especially in bacilliferous lepromatous cases.
36例未经治疗的界限类偏瘤型/瘤型(BL/LL)麻风患者,初始细菌指数(BI)为4+至6+,被依次分配到三个治疗组。第一组患者接受略作修改的世界卫生组织方案(利福平每月一次,氯法齐明和氨苯砜每日服用),并皮内注射卡介苗(i.d.)(0.1毫克/剂)。第二组患者接受相同的多药联合化疗(MDT)并皮内注射灭活的w型分枝杆菌(2×10⁸/剂),第三组接受相同的MDT并皮内注射0.1毫升蒸馏水。每6个月重复接种一次。在接种部位及背部等远处部位进行活检。通过临床、组织病理学和细菌学(BI、鼠足垫、ATP)参数定期监测病情进展。25例患者完成了2年以上的随访。其中:第一组7例,第二组10例,第三组8例。MDT+卡介苗组中1例病情进展良好的患者在28个月后退出。在联合化疗和免疫治疗的病例中,6个月后(12个月及以后)通过鼠足垫和ATP测量未发现活的杆菌。然而,在仅接受MDT的部分对照病例中,甚至在18个月(通过鼠足垫)和2年(通过ATP估计)时仍可检测到活的杆菌。经过36个月的治疗,仅接受MDT的组(对照组)平均BI从4.64+降至1.66+,MDT+卡介苗组从4.9+降至0.08+,MDT+w型分枝杆菌组从4.75+降至0。与MDT组和MDT+卡介苗组相比,MDT+w型分枝杆菌组在12、18和24个月时BI下降更为显著。虽然w型分枝杆菌组的所有病例在36个月时涂片均转为阴性,但卡介苗组所有病例达到阴性则需要42个月。免疫治疗似乎对杆菌的杀灭和清除有显著作用,应被视为化疗的辅助手段,尤其是在有菌的瘤型病例中。